Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy.

被引：3
|
作者：
Shapiro, Irina
Grote, Hans Juergen
D'Urso, Vittorio
von Heydebreck, Anja
Mahnke, Lisa
Kaufman, Howard
Nghiem, Paul
Cal, Ti
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9557
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9557
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab.
    Bullement, Ash
    D'Angelo, Sandra P.
    Amin, Amerah
    Stapelkamp, Ceilidh
    Willis, Anna
    Lilley, Cameron
    Hatswell, Anthony
    Bharmal, Murtuza
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
    Cowey, C. Lance
    Mahnke, Lisa
    Espirito, Janet
    Helwig, Christoph
    Oksen, Dina
    Bharmal, Murtuza
    FUTURE ONCOLOGY, 2017, 13 (19) : 1699 - 1710
  • [33] Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (US) from SPEAR-Merkel: Study informing treatment pathway decisions in Merkel cell carcinoma (MCC).
    Bhanegaonkar, Abhijeet
    Liu, Frank Xiaoqing
    Kim, Ruth
    Boyd, Marley
    Fulcher, Nicole
    Krulewicz, Stan
    Kasturi, Vijay
    Cowey, Charles Lance
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [34] Self assessment of buccodental toxicity: Comparison of patients with metastatic renal cell carcinoma (RCC) treated with sunitinib with patients treated with chemotherapy.
    Gilabert, M.
    Provansal, M.
    Cappiello, M.
    Walz, J.
    Brunelle, S.
    Salem, N.
    Gravis, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
    Kaufman, Howard L.
    Russell, Jeffery S.
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    von Heydebreck, Anja
    Hennessy, Meliessa
    Nghiem, Paul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [36] COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA
    Avxentyev, N. A.
    Frolov, M.
    Makarov, A.
    Palencia, R.
    Kudelya, O., V
    Kovaleva, E. R.
    VALUE IN HEALTH, 2019, 22 : S511 - S511
  • [37] Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (US) from SPEAR-Merkel -Study informing treatment Pathway dEcisions in Merkel cell cARcinoma (MCC).
    Cowey, Charles Lance
    Liu, Frank Xiaoqing
    Kim, Ruth
    Boyd, Marley
    Fulcher, Nicole
    Krulewicz, Stan
    Kasturi, Vijay
    Bhanegaonkar, Abhijeet
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES: AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA
    Bullement, A.
    Amin, A.
    Stapelkamp, C.
    Willis, A.
    Lilley, C.
    Hatswell, A. J.
    Pescott, C.
    Bharmal, M.
    VALUE IN HEALTH, 2018, 21 : S11 - S11
  • [39] Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
    Lebbe, C.
    Nghiem, P.
    Bhatia, S.
    Mortier, L.
    Brohl, A. S.
    Jacob, N.
    Tyroller, K.
    Hoffman, J.
    D'Angelo, S. P.
    ANNALS OF ONCOLOGY, 2024, 35 : S744 - S745
  • [40] Association between objective responses (OR) and overall survival (OS) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab.
    D'Angelo, Sandra P.
    Hunger, Matthias
    Schlichting, Michael
    Hennessy, Meliessa G.
    Bharmal, Murtuza
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
12345